Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003765 · ClinicalTrials.gov registry record · Phase 1
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT00003765: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by National Cancer Institute (NCI).
NCT00003765 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003765, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase I trial to study the effectiveness of O6-benzylguanine and carmustine in treating children who have refractory CNS tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Conditions Studied
Interventions
- DRUG O6-benzylguanine
- DRUG carmustine
Study Locations (20)
California
- University of California San Diego Cancer Center - La Jolla
- Children's Hospital Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- City of Hope National Medical Center - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Cancer Center and Cancer Research Institute - San Francisco
- Stanford University Medical Center - Stanford
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
- Children's Memorial Hospital, Chicago - Chicago
Massachusetts
- Boston Floating Hospital Infants and Children - Boston
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Children's Hospital of Michigan - Detroit
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- University of Florida Health Science Center - Gainesville
Georgia
- Emory University Hospital - Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1999-05 |
| Phase | Phase 1 |
What the finished NCT00003765 record still lists
NCT00003765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which O6-benzylguanine is the first listed.
NCT00003765 names 20 study sites across 11 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00003765 about?
NCT00003765 is a clinical study titled "O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors". Phase I trial to study the effectiveness of O6-benzylguanine and carmustine in treating children who have refractory CNS tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
What is the current status of trial NCT00003765?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 1999-05.
What conditions does trial NCT00003765 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003765?
The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).
Who is sponsoring clinical trial NCT00003765?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003765 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003765's enrollment target sits among peer trials
36 28th of 45 higher than 18 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia